Ashish M. Kamat, MD, MBBS

I had the pleasure of meeting @UroDocAsh - so clearly driven by wanting more and better for patients (all, not just his). Grateful every time I get to know a doctor who is both brilliant and empathetic. #bladdercancer #PatientCare #patientsfirst

A profound honor – this generous gift by Toby Shor is a tribute to bladder cancer patients, the care that makes survivorship possible, and the remarkable team I’m privileged to work with. @MDAndersonNews #OncSurgery @NNavai @KKBree @DrByronLee @OAlhalabiMD @DocMattCampbell…

What an amazing keynote presentation from our VP @UroDocAsh during our @CityofHope Annual GU Research Retreat organized by @MontyPal and @TDorffOnc. A visit full of inspiring discussions for future collaboration over delicious food (can always trust @ClaytonLauMD with the menu)

Stellar presentation by keynote speaker @UroDocAsh on bladder-sparing options in muscle-invasive disease and nuances of intermediate-risk NMIBC. 🔵 Presented at the 2nd @CityofHope_GU @cityofhope retreat, made possible by incredible team of physicians led by @WesleyYipMD…

Elsa, the FDA's AI assistant, faces criticism for producing unreliable and fabricated information. Internal reports describe Elsa as "clunky" and prone to "hallucinations," contrasting with the agency's positive public messaging. medicaleconomics.com/view/fda-s-new…

I really enjoyed this conversation with @UroDocAsh @UroToday where we discussed how AI and deep learning are transforming how we think about cancer treatment, especially in bladder cancer. We discussed our work using AI to integrate data streams from the lab and the clinic to…

I often hear that post-TMT cystectomy is “fraught with complications even in experienced hands.” That hasn’t been my experience. With the right principles and disciplined technique, these cases can be remarkably straightforward. Maybe I’m delusional - but curious to hear what…

Discussions with seasoned clinician scientist @UroDocAsh to explain the #BioShield and the importance of NK cells and T cells. #Lymphocytes matter. It is important to catch cancer as early as possible. @SecKennedy

J&J receives @US_FDA Priority Review for TAR-200 in high-risk NMIBC Phase 2b SunRISe-1 study #AUA25 ✅82.4 % CR rate ☑️ 52.9 % cancer-free at least one year after CR jnj.com/media-center/p…

Longer follow up for Enfortumab Vedotin & Pembro in urothelial cancer @Annals_Oncology shows mOS at nearly 3 yrs (34 mnths) with 50% of responses (68%) continuing at 2 years! Experience in tox management is important. Duration of therapy uncertain in CR gbr01.safelinks.protection.outlook.com/?url=https%3A%…

TROPION-PanTumor01 trial for advanced #BladderCancer. @UroDocAsh interviews Dr. Funda Meric-Bernstam @MDAndersonNews on the #TROPIONPanTumor01 trial results in #urothelialcancer. #DatoDXd shows a 25% ORR in heavily pretreated patients, with 76% maintaining disease control at 6…

AI risk calculator outperforms EAU models for #BladderCancer prognosis. Alexandre Zlotta, MD, PhD, FRCSC @SinaiHealth joins @UroDocAsh @MDAndersonNews to discuss the evolution of AI in bladder cancer management. #WatchNow > bit.ly/3ZThW4i

A lifeline for ongoing progress in the field @BladderCancerUS @NIH @IBCG_BladderCA @PGrivasMDPhD @montypal @m_e_nielsen @SpiessPhilippe @FaltasLab @zklaassen_md @brian_rini @JoshMeeks @TiansterZhang @siadaneshmand @ERPlimackMD @shilpaonc @UroDocAsh @LauraBukavinaMD @sonpavde…

Micropapillary histology in #BladderCancer: a retrospective survival analysis. @AlkazemiMD @UrologyMSK & @h_alahmadie @MSKCancerCenter join @UroDocAsh @MDAndersonNews to discuss a study on micropapillary bladder cancer where findings show worse survival vs. conventional UC (37…

#CheckMate274 analysis shows improved outcomes for #BladderCancer patients with adjuvant nivolumab. @MattGalsky @TischCancer sits down with @UroDocAsh @MDAndersonNews to discuss on UroToday. 🔹 DFS benefit, esp. in PD-L1-high pts 🔹 Neoadjuvant chemo? Nivo benefit remains 🔹…

#CREST trial first interim analysis: Extending event-free survival and advancing care in high-risk #NMIBC. Neal Shore, MD, FACS @CURCMB joins @UroDocAsh @MDAndersonNews discussing CREST trial results demonstrating superior event-free survival with a hazard ratio of 0.68,…

U.S. National Institutes of Health (NIH) announces that it will no longer seek research proposals for projects involving animals; all new agency funding opportunities will need to be on human biology/include nonanimal methods. pcrm.org/news/news-rele…

What are biomarkers? Why do they matter? It may sound like a distant concept, but all we need as patients and care partners are doctors like @UroDocAsh who can explain simply and in a way that makes clear the impact of this knowledge and understanding ✅. #bladder #cancer…

1/5 How reproducible are phase III oncology trials? 📊 With @AlexSherryMD @ErikVanZwet @ebludmir et al. We analyzed 632 RCTs (~496,000 pts). The data offer both reassurance and caution for clinicians and researchers. pubmed.ncbi.nlm.nih.gov/40628175/ 👇#MsaouelLab

Cystectomy vs. Bladder Preservation: Weighing Options for Muscle-Invasive Bladder Cancer #MIBC. @BogdanaSchmidt @huntsmancancer & @mouwlab @DanaFarber join @UroDocAsh @MDAndersonNews in a debate on treatment options for muscle-invasive bladder cancer. #WatchNow on UroToday >…